Blog Detail
Recent Posts
Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science
Fluxion Biosciences announced today that it has expanded its sales and service network into Asia. The company signed a distribution agreement for its BioFlux™ line with Korea-based DI Biotech. A second agreement with Novel Science covers sales of b...
Amgen/GSK’s Prolia will be preferred as second- or third-line therapy for osteoporosis
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline’s Prolia as either a second- or th...
Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial
After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics’ experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatme...
AAD SEAL OF RECOGNITION program to be phased out
The American Academy of Dermatology (AAD) has decided to phase out its AAD SEAL OF RECOGNITION(R) program over the next two years, and will cease accepting new applications effective immediately. Products which were accepted into the program prior to...
“Soft individual mandate” in the healthcare bills raises concern
Lockton Benefit Group is providing employers with a comprehensive, practical view on proposed health reform legislation working through Congress....
PPD introduces new centralized computing platform for analysis and reporting of clinical trial data
PPD, Inc. today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data. The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the co...
